In vivo gene editing of CAMKIID: out with the bad and in with the good
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci176672 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von John E Smith und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
The ability to change an organism's DNA through gene editing is of great importance for the prevention and treatment of genetic and acquired diseases. Rapid progress has been made during the last decade due to the discovery and refinement of CRISPR/Cas9 as an accurate, fast, and reliable genome editing technique. In this issue of the JCI, Lebek et al. present the culmination from a line of work in the Olson laboratory focused on in vivo gene editing of CAMK2D. The paper presents a combined state-of-the-art gene therapy approach that demonstrates how gene therapy can yield cardioprotection in a mouse model and takes notable steps toward potential applicability in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- NHLBI NIH HHS
Zitieren
APA
Smith, J. E., & Granzier, H. (2024). In vivo gene editing of CAMKIID: out with the bad and in with the good. Journal of Clinical Investigation. https://doi.org/10.1172/jci176672
Vancouver
Smith JE, Granzier H. In vivo gene editing of CAMKIID: out with the bad and in with the good. Journal of Clinical Investigation. 2024. doi:10.1172/jci176672
BibTeX
@article{Smith2024,
author = {Smith, John E and Granzier, Henk},
title = {In vivo gene editing of CAMKIID: out with the bad and in with the good},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci176672}
}
EUVIMED